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Abstract.  In this study we have used complementary 
biochemical and immunological techniques to establish 
that the lymphoma GP85 membrane glycoprotein is a 
transmembrane protein with a cytoplasmic domain that 
binds directly to ankyrin, a molecule known to link 
the membrane to the cytoskeleton. 
The evidence supporting our conclusion that the 
GP85 is a transmembrane glycoprotein is as follows: 
(a) GP85 can be surface-labeled with Na~25I and con- 
tains wheat germ agglutinin-binding sites, indicating 
that it has an extracellular domain; (b) GP85 can be 
phosphorylated by intracellular kinases, indicating that 
it has an intracellular domain; and (c) GP85 can be 
successfully incorporated into phospholipid vesicles, 
indicating the existence of a hydrophobic domain in 
the molecule. Further studies show that GP85 displays 
immunological cross-reactivity with the lymphocyte 
Pgp-1 (differentiation-specific) membrane glycoprotein, 
and with the erythrocyte anion transport membrane 
protein, band 3. 
Immunocytochemical studies indicate that an 
ankyrin-like protein accumulates underneath the lym- 
phoma GP85 cap structure, suggesting an association 
of the ankyrin-like protein and GP85.  This relationship 
has been further confirmed by the following results of 
binding and reconstitution experiments: (a) purified 
GP85 binds directly to an ankyrin-Sepharose column; 
(b) purified GP85 inserts into phospholipid vesicles in 
both the normal (fight side out) and reversed (inside 
out) orientation (and with only the reversed configura- 
tion permits binding of ankyrin to GP85); and (c) 
cleavage of GP85 with trypsin yields a 40-kD peptide 
fragment that is part of the cytoplasmic domain and 
contains the ankyrin binding site(s). Based on these 
findings, we suggest that the lymphoma GP85 trans- 
membrane glycoprotein contains a cytoplasmic domain 
that is directly involved in linking ankyrin to the 
cytoskeleton. This transmembrane linkage may play a 
pivotal role in receptor capping and cell activation in 
lymphocytes. 
I 
NTERACTIONS between cytoskeletal proteins and the cy- 
toplasmic  domains of transmembrane proteins  are be- 
lieved to play a key role in several cellular activities, in- 
cluding ligand-induced receptor patching and capping (11, 27, 
35, 36), attachment of the cell surface to adhesion substrate 
(21, 45), cell activation and proliferation  (21), cell motility 
(21), and cell-cell interaction  (21). 
The associations between transmembrane proteins and the 
cytoskeleton have been studied in great detail with erythro- 
cytes. For example, purified cytoskeletal proteins have been 
bound to inside-out erythrocyte  membrane vesicles in order 
to demonstrate that specific linkage molecules are required 
for the association between the cytoplasmic domain of trans- 
membrane proteins  and the cytoskeletal molecules (6, 38). 
These studies have found that glycophorin, the major eryth- 
rocyte membrane glycoprotein, is linked to the actin-binding 
protein, spectrin, via band 4.1 (1, 17). Similarly, band 3, the 
anion transport channel,  is  linked  to  spectrin  (7)  via the 
linker protein, ankyrin (4, 40). Furthermore, the linkage be- 
tween glycophorin and band 4.1 appears to be regulated by 
polyphosphoinositides  (2), and the band 3 ankyrin-binding 
site has been identified as a 40-43-kD amino-terminal  pro- 
teolytic fragment that contains the most heavily phosphor- 
ylated region of the band 3 cytoplasmic domain (40). 
Analogs  to proteins  of the erythrocyte membrane-cyto- 
skeleton complex such as spectrin  (10, 23),  ankyrin (5, 9), 
protein 4.1 (3, 8, 15, 22), glycophorin (12), and band 3 (19) 
have been found in a number of nonerythroid cells (29). In 
particular,  a number of immunoreactive forms of the eryth- 
rocyte band 3-like molecule have been found in different cell 
types,  including  lymphocytes,  platelets,  leukocytes,  adult 
liver cells, lung carcinoma cells, embryonic liver cells, and 
normal human fibroblasts (29). Further biochemical studies 
indicate that these band 3-like molecules are present as 60-, 
48-, and 38-kD polypeptides in lung cell membrane (29), as 
69-  and 60-kD  polypeptides  in neoplastic  cell membrane 
(29),  and  as  85-95-kD  polypeptides  in  white blood  cell 
membrane (29). 
Recently,  Bourguignon  and  co-workers  have  identified 
several membrane-cytoskeleton  protein complexes in T lym- 
phocytes.  These include:  (a) a complex that  contains  the 
membrane glycoprotein,  GP180, and fodrin (a spectrin-like 
molecule), which binds to actin (10, 44); (b) a complex that 
consists of Thy-1 antigen and a 4.l-like protein that binds to 
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membrane glycoprotein, GP85, and an ankyrin-like protein 
that also binds to fodrin and actin. The association between 
lymphoma GP85 and the ankyrin-like molecule appears to 
be analogous to that occurring between band 3 and ankyrin 
in erythrocytes (9). 
In this study we have used complementary  biochemical 
and immunological techniques to further examine the trans- 
membrane interaction occurring between lymphoma GP85 
and the ankyrin molecule in mouse T-lymphoma cells. We 
speculate that this interaction may play a pivotal role in the 
mechanism of receptor  capping and activation of lympho- 
cytes. 
Materials and Methods 
Cell Culture 
The mouse T lymphoma BW 5147 cell line (an AKR/J lymphoma line) was 
provided by Dr. R. Hyman (The Salk Institute, San Diego, CA). The cells 
were grown at  37*  in 5%  CO2/95%  air using DME supplemented with 
10% heat-inactivated horse serum (Gibco, Grand Island, NY), 1% penicil- 
lin, and  i%  streptomycin. 
Protein Phosphorylation 
Two procedures were used to metabolically label cellular phosphoproteins. 
Ha32PO4 (carrier free; ICN K&K Laboratories Inc., Plainview,  NY) was 
added to cells in culture at 25 laCi/ml for 1 h or at 2 laCi/ml for 18 h. Radio- 
actively labeled cells were washed and used for membrane preparations. 
Radioactive Labeling of Cellular Proteins 
Surface proteins and  isolated cellular proteins were labeled with Na~ZSI 
using the iodogen method of Fraker and Speck (20). 
Plasma Membrane Isolation 
T lymphoma cells (nonradioactively labeled, surface 125I labeled, or meta- 
bolically 32PO4 labeled) were harvested by low speed centrifugation (500 
g~), washed twice with a phosphate-buffered Earle's salt solution (pH 7.3), 
and washed once in 20 mM Hepes (pH 7.3),  2 mM EDTA, 1 mM mercap- 
toethanol (HEM). Cells wore then resuspended in HEM buffer containing 
1 mM phenylmethylsulfonyl  fluoride (PMSF), 10 lag/ml aprotinin, 10 lag/nil 
leupeptin, and 5 mM iodoacetamide and lysed using a Dounce homogen- 
izer. The lysate was centrifuged at 750 g, for 5 min at 4~  to remove nu- 
clei, cell debris, and unlysed cells. The supernatant was then recentrifuged 
at 43,000 g~ for 20 min to pellet crude membranes. The crude membranes 
were resuspended in a solution containing 10% wt/wt sucrose made in HEM 
buffer plus 1 mM PMSE 10 lag/ml aprotinin, 10 lag/ml leupeptin, and 5 mM 
iodoacetamide. This membrane suspension was layered over a discontinuous 
gradient of 20, 30, and 40% wt/wt sucrose made in the same buffer and then 
centrifuged at 100,000 8~* for 2 h. The purified plasma membrane fraction 
was collected from the 30-40% interface (28) and washed with Dulbecco's 
PBS.  Enzyme marker assays (5'-nucleotidase and/or Na+/K+-ATPase  ac- 
tivities)  demonstrated that  the  plasma  preparation  was  at  least  20-fold 
purified and contained negligible amounts of other membranous organelle 
contaminants. 
Isolation of  Human Erythrocyte Ankyrin 
Human erythrocyte ankyrin was isolated by the procedure of Bennett and 
Stenbuck (7). 
SDS-PAGE and Autoradiographic Analysis 
Unless otherwise indicated, one-dimensional SDS-PAGE was conducted 
using a linear polyacrylamide gradient (5-15 %) slab gel and a discontinuous 
buffer system described by Laemmli (31). In the case of two-dimensional 
SDS-PAGE the following conditions were used. For the first dimension, 
isoelectric focusing gels containing 1% ampholytes, pH 3.5-10.0,  and 4% 
ampholytes, pH  5-7  (LKB Instruments, Inc.,  Gaithersburg,  MD),  were 
used. Linear (5-15%) polyacrylamide gradient gels were used (37) for the 
second dimension. For autoradiographic analysis, all gels were vacuum- 
dried, exposed to Kodak X-ray (X-Omat XAR-5) film, and quantitated by 
densitometric tracing. 
Negative Staining Procedures 
Negative staining was done by adding three successive drops of liposomes 
to 0.2% Formvar-coated grids (200 mesh) and drying this with filter paper. 
Three drops of 1% uranyl acetate in water (pH 4.5) were then applied to the 
samples for 30 s and removed with filter paper. The samples were then ex- 
amined in a Phillips 300 electron microscope. 
Triton X-IO0 Extraction of  Lymphoma Membranes 
Crude or purified plasma membranes (nonradioactively labeled, surface 
125I labeled, or metabolically 32po4 labeled) were resuspended in a  solu- 
tion containing 50 mM Tris-HC1 (pH 7.4),  5 mM EDTA, 1 mM PMSF, 10 
p.g/ml aprotinin, 10 lag/ml leupeptin, 5 mM iodoacetamide, and 1% Triton 
X-100. The sample was incubated at 4~  for 1 h with constant shaking and 
centrifuged at 43,000 g~ for 20 min. The 43,000 g~ pellet fraction (Triton 
X-100-insoluble material) was discarded and the suporoatant fraction (Tri- 
ton X-100-soluble material) was collected for the following wheat germ ag- 
glutinin (WGA)-Sepharose column chromatography analysis. 
WGA-Sepharose Column Chromatography 
Lymphoma membranes (nonradioactively labeled, surface ~2sI labeled, or 
metabolically 3zpo4  labeled) solubilized in Triton X-100 were incubated 
with 2 M urea/l.5 M NaCI and mixed with WGA-sepharose  beads overnight 
at 4~  with constant shaking. The beads were then packed into a column 
and washed with 20 column volumes of a solution containing 50 mM Tris- 
HCI (pH 7.4), 5 mM EDTA plus 2 M urea. After washing offunbound mate- 
rial, the WGA-binding proteins were eluted from the column with a solution 
containing 0.75 M N-acetyi-glucosamine (GIcNAc), 50 mM Tris-HCl (pH 
7.4),  5  mM EDTA,  and  1%  deoxycholate. These WGA-binding proteins 
were used for the following liposome incorporation and various immuno- 
precipitation experiments. 
Purification of Lymphoma GP85 
WGA-specific binding proteins (nonradioactively labeled or surface ~25I la- 
beled) were isolated by WGA-Sepharose affinity  chromatography as de- 
scribed above. These proteins were concentrated using a microconcentrator 
(centricon 30; Scientific Systems Division, Amicon Corp., Danvers, MA), 
and applied to a 5-15% gradient SDS-gel. After electrophoresis, the pro- 
tein band corresponding to GP85 was excised, eluted from the gel, and fur- 
ther iodinated (in order to label the entire GP85  molecule with a  high 
specific activity)  by  the  iodogen method as described previously.  This 
purified radioactively labeled GP85 was used in the ankyrin-binding assays 
and peptide mapping analysis as described below. 
Peptide Mapping of u~I-Surface-labeled GP85 
Peptide mapping of GP85 was done using the method described by Cleveland 
et al.  (14).  125I-surface-labeled  GP85  was purified through WGA-affinity 
column  chromatography  and  analyzed  on  one-dimensional SDS-PAGE 
using a 5-15%  linear polyacrylamide gradient gel and the discontinuous 
buffer system described by Laemmli (31). The protein bands corresponding 
to t25I-GP85 were excised and transferred into the sample wells of a second 
dimension 15%  SDS-gel. Variable amounts of V-8 proteinase (e.g., 0,  1, 
or 5 lag) were added to the GP85-containing wells. Gel electrophoresis was 
carried out at 32 mA until the V-8 treated GP85 migrated in the middle of 
the stacking gel. Electrophoresis was stopped for 15 rain to allow proteolytic 
digestion to occur. Subsequently, peptide fragments of  GP85 digested by V-8 
were subjected to further electrophoresis at a constant current of 20 mA 
using the discontinuous buffer system described by Laemmli (31). Autoradio- 
graphic analyses of these gels were carried out according to the procedures 
described above. 
Alkali Treatment of3zP-labeled GP85 
Some  SDS-polyacrylamide gels  containing  3zPO4-1abeled proteins were 
treated with 1 M  KOH solution and placed in a 55~  water bath for 2 h 
with occasional agitation. The alkali solution was decanted from the gel and 
1. Abbreviation  used in this paper:  WGA, wheat germ agglutinin. 
The Journal  of Cell Biology,  Volume 106, 1988  320 replaced with a solution containing 10% acetic acid and 10% isopropanol. 
The container was gently swirled at room temperature for 2 h, during which 
time the solution was changed at least three to four times. The gel was then 
allowed to swell back to its original size in H20. It was then dried and sub- 
jected to autoradiography as described above. 
Phosphoamino Acid A nalysis 
32po4-1abeled  lymphoma  membrane  glycoprotein  GP85  purified  using 
WGA-Sepharose  affinity  chromatography  was  subjected  to  SDS-PAGE 
analysis. The protein band corresponding to GP85 was excised and eluted 
from the pelyacrylamide gel by electroelution using the method described 
by Hunkapiller et al. (25), The eluted GP85 was hydrolyzed at I10~  for 
2 h by the method described by Cooper et al. (16), and the phosphoamino 
acids  were  separated  on  3-ram  chromatographic  paper  0Vhatman Inc., 
Clifton, NJ) at pH 3.5 for 2 h at 2,000 V. The phosphoamino acid standards 
(i.e., phosphoserine, phosphotyronine, and phosphothreonine) were mixed 
with 32PO4-1abeled samples, coanalyzed, and identified by minhydrin stain- 
ing. The 32PO4-1abeled phosphoamino acids were detected by autoradiog- 
raphy (X-Omat XAR-5 film) at  -70~ 
lmmunoprecipitation Procedures 
An aliquot of affinity-purified surface 12SI-labeled lymphoma GP85 was in- 
cubated with either rat antilymphocyte Pgp-1  monoclonal antibody (pro- 
vided by Dr. Hyman), or rabbit antierythrocyte band 3 antiserum (provided 
by Dr. Bennett) for 1 h at 4~  As controls, either anti-Pgp-I or anti-band 
3 antibody was ommitted, or preabsorbed serum (rat anti-Pgp-l-free serum 
or rabbit anti-band 3-free serum) was used. Subsequently, goat anti-rat IgG 
or goat anti-rabbit IgG at 100 Ixg/ml was added to the rat anti-Pgp-I  (or 
anti-Pgp-l-free serum, control samples) or rabbit anti-band 3 (or anti-band 
3-free serum, control samples)-reacted samples, respectively. These sam- 
ples were incubated at 4~  overnight.  The resulting immunoprecipitates 
were centrifuged at 700 g~ for  10 min to form pellets, and washed three 
times with a solution containing 50 mM Tris-HCl buffer (pH 7.4),  5 mM 
EDTA, and 3 % deoxycholate using the same centrifugation conditions. The 
immunoprecipitates  were  solubilized  in a  solution of 20  mM  Tris-HCI 
buffer (pH 7.4) containing 0.1 M 2-mercaptoethanol, 2% SDS, and 0.003 % 
bromophenol blue. These proteins were then analyzed by SDS-PAGE in a 
5-15 % exponential gradient gel and by autoradiography. 
Incorporation of  Lymphoma GP85 into Phospholipid 
Vesicles (Liposomes) 
L-lecithin (10 nag) and phosphatidyl serine (1 rag) (Avanti Polar Lipids, Inc., 
Birmingham, AL) were lyophilized and dissolved in 2 ml of a solution con- 
taining 3% cholate, 50 mM Tris-HCl (pH 7.4), and 5 mM EDTA. This lipid 
solution was then mixed with lymphoma glycoproteins (100 gg/rnl) (either 
~25I-surface labeled,  metabolically  32PO4 labeled,  or unlabeled)  isolated 
from the WGA-Sepharose column as described above for "~1 h at room tem- 
perature. The protein/lipid mixture was then dialyzed for 2 d in 2 liters of 
50 mM Tris-HCI (pH 7.4), 5 mM EDTA. This dialysis buffer was changed 
twice to remove the free detergent. The liposomes were layered over a dis- 
continuous step-gradient consisting of 60, 40, 25, and 10% wt/vol sucrose 
made in 50 mM Tris-HCl (pH 7.4), 5 mM EDTA and then centrifuged at 
120,000 g~ for 18 h at 4~  Control liposomes in which no protein was in- 
corporated were prepared in an identical manner. Some 32PO4-GP85-con- 
taining liposomes  were  incubated with  trypsin conjugated  to Sepharose 
beads (trypsin-Sepharose or immobilized trypsin) (100 gg/ml) at 22 ~ for 
10 min to remove the 32PO,-labeled cytoplasmic domain of GP85,  which 
was protruding from the outside surface of the liposomes. At the end of the 
trypsinization reaction, the trypsin beads were centrifuged at 1,000 g,~ for 
5 min. The liposomes (with or without trypsin treatment) were selectively 
banded on the top of the 10% sucrose. The gradients were fractionated from 
top to bottom and assayed for radioactivity to determine the location of 
liposome-associated ~25I- or 32po4-1abeled  glycoproteins. Radioactively la- 
beled samples from the gradients were analyzed by SDS-PAGE and autora- 
diography as described above. Unlabeled proteins that were successfully in- 
corporated into liposomes were used for ankyrin binding experiments. 
ml-Ankyrin Binding to GP85 Containing 
Phospholipid Vesicles (Liposomes) 
The unlabeled GP85-containing phospholipid vesicles  (liposomes) were 
incubated with  125I-ankyrin  for 2  h  at 4~  These  liposomes were then 
passed through a Sepharose 2B-300 column to separate t2~l-ankyrin-bound 
liposomes (preferentially eluted at the void volume) from free 125I-ankyrin. 
To determine nonspecific binding of ~2SI-ankyrin to the liposomes, either 
GP85-containing liposomes that were treated with trypsin or pbospholipid 
vesicles that contained no protein were used in this ~25I-ankyrin binding 
assay. 
mI-GP85 Binding to Ankyrin-conjugated 
Sepharose Beads 
Ankyrin was purified from 40-ml erythrocyte ghosts using the procedure 
of Bennett and Stenbuck (7). This protein was then concentrated and con- 
jugated to Scpharose-beads overnight at 4*(2. Unbound sites were satorated 
with I M ethylamine (pH 9.0) overnight. The beads were then washed exten- 
sively with a solution of 0.5 M NaC1, 0.1 M acetate (pH 4.0) buffer and then 
with a solution of 0.5 M NaCl, 0.1 M Tris-HC1 (pH 8.0) buffer. After three 
washes they were washed with Dulbecco's modified PBS.  An aliquot of 
beads (100  gl) was mixed with l~SI-laboled GP85 (1  x  106 cpm) and al- 
lowed to bind at 4~  overnight. In control experiments ~I-labeled lym- 
phoma GP85 was incubated overnight with soluble ankyrin (100 gg/ml) and 
this mixture was then added to the ankyrin beads. 
Identical ankyrin-binding experiments  were performed  using trypsin- 
treated  ~25Iqabeled  lymphoma GP85.  The preparation of trypsin-treated 
GP85 was as follows.  12~I-labeled GP85 (100 gg/ml) was incubated with 
trypsin that was conjugated to Sepharosr beads (100 gg/ml) (trypsin-Sepha- 
rose or immobilized trypsin) at 35~  for 10 rain with constant shaking. The 
trypsinization reaction was terminated by adding  100 mM PMSF (with a 
final  PMSF  concentration of  10 raM).  Subsequently,  trypsin-Sepharose 
beads were centrifuged at 10,000 g,v for 4 rain. The trypsin-digested GP85 
polypeptide fragments were used to bind ankyrin-Sepharose beads as de- 
scribed above. 
After binding,  the  beads  were  transferred  in disposable  l-ml  plastic 
columns and washed extensively with Dulbecco's modified PBS. The degree 
of radioactive binding was determined by counting the beads with a gamma 
counter (model 5500; Beckman Instruments, Inc., Palo Alto, CA). The pro- 
tein was then recovered by eluting it with 200 t~l of a solution containing 
20 mM Tris-HCl (pH 6.8), 2 % SDS, 0.1 M 2-mereaptoethanol, and 0.003 % 
bromophenol blue. The eluted protein was examined by one-dimensional 
SDS-PAGE using a 5-15% linear gradient gel followed by autoradiography. 
Results 
Identification of  Lymphoma GP85 as a 
Transmembrane Protein 
Determination  of the GP85 transmembrane  characteristics 
was achieved by surface labeling techniques,  internal 32PO4 
labeling, and liposome binding studies. Our results showed 
that:  (a) GP85 could be surface iodinated (Fig.  1, lane C); 
(b) GP85 bound to a WGA-Sepharose column and was spe- 
cifically eluted with N-acetyl glucosamine (Fig.  1, curves A 
and B) (both of these findings indicate that GP85 is a surface 
glycoprotein); and (c) GP85 could be phosphorylated by in- 
tracellular kinase(s) (Fig.  1, lane D). Analysis of the phos- 
phorylated  GP85  suggested that  this  phosphorylation  was 
sensitive to alkali  treatment  (Fig.  2 A,  lane  1 vs.  lane 2) 
that  preferentially  removed  serine  and  threonine,  but not 
tyrosine, residues. Phosphoamino acid analysis revealed that 
the phosphorylation  of GP85 occurred primarily  at serine 
and threonine residues (Fig. 2 B). Therefore, the phosphor- 
ylated portion of GP85 (presumably at the cytoplasmic do- 
main)  may serve as an intracellular  substrate primarily  for 
serine- and threonine-specific, but not tyrosine-specific, ki- 
nases.  Finally  (d) GP85 labeled with  ~25I and 32po4 could 
be successfully incorporated into phospholipid vesicles, as 
shown in  Fig.  3  (curves A and B).  After sucrose density 
gradient  centrifugation,  the liposomes containing  125I- and 
32PO4-1abeled protein banded on the top of the gradient (Fig. 
3, curves A and B). SDS-PAGE and autoradiographic analy- 
sis of the gradient  indicated  that the  liposomes were spe- 
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Sepharose column chromatography. Both  ~25I-surface-labeled  or 
metabolically 32po4-1abeled lymphoma plasma membranes were 
extracted by Triton X-100, followed by centrifugation at 43,000 g~v 
for 20 min. The Triton X-100-soluble materials (the supernatant 
fraction  of the  43,000 gay centrifugation)  were  passed  through 
WGA-Sepharose columns in the presence of 2 M urea and 1.5 M 
NaC1. Subsequently, the WGA-Sepharose  column-bound proteins 
were eluted with 0.75 M N-acetyl-glucosamine (GlcNAc) (GlcNAc, 
arrow) as described in Materials and Methods. (Curve A) The elu- 
tion  profile  of  GlcNAc-eluted  WGA-Sepharose column-bound 
membrane  glycoproteins (~25I-surface labeled).  (Curve  B)  The 
elution profile of GlcNAc-eluted WGA-Sepharose column-bound 
membrane glycoproteins (metabolically 32po4 labeled). (Lane C) 
Autoradiogram of 125I-labeled membrane glycoproteins obtained 
from curve A using SDS-PAGE and autoradiographic analyses. 
(Lane D) Autoradiogram of 32PO4-1abeled membrane glycopro- 
teins obtained from curve  B using SDS-PAGE  and autoradiographic 
analyses. 
Figure 2. Alkali treatment and 
phosphoamino  acid  analysis 
of metabolically 32PO4-1abeled 
lymphoma  GPg5  glycopro- 
rein.  Metabolically 32PO4-1a- 
beled  WGA-binding proteins 
were isolated and analyzed by 
SDS-PAGE/autoradiography 
as described above in Fig.  1. 
(A) Autoradiogram of 32po4- 
labeled  WGA-binding  pro- 
teins without alkali treatment 
(lane 1) or with alkali (1,0 M 
KOH)  treatment  to  remove 
32PO4 from serine and threo- 
nine residues (lane 2). (Note 
that the 32po4-1abeled  protein 
band  corresponding  to  the 
GP85 was absent after alkali treatment.) (B) Autoradiogram of 
32PO4-1abeled GP85 that was eluted from the gel (as shown in A, 
lane 1) and processed through phosphoamino acid analysis. (Note 
the presence of  phosphoserine [P-Ser], phosphothreonine [P-Thre], 
but not phosphotyrosine [P-Tyr]. 
cifically enriched for GP85 (Fig. 3,  lane C).  The fact that 
GP85 can be incorporated into phospholipid vesicles implies 
the existence of a hydrophobic domain in the molecule that 
is required for all transmembrane proteins. 
Immunological Analysis of  Lymphoma GP85 
GP85 was found to cross-react with antibodies specifically 
raised  against  lymphocyte Pgp-1 glycoprotein (Fig.  4  A). 
GP85's molecular mass,  isoelectric point (PI), ~4.5 to 5.0 
(Fig. 5), and peptide mapping pattern (Fig. 6 A-C) were very 
similar to those of Pgp-1. In addition, GP85's cross-reactivity 
with the erythrocyte  band 3 molecule suggests that this pro- 
tein  is  an  immunoreactive form of band  3-like  molecule 
(Fig. 4 B).  No GP85-associated material was  observed in 
control samples when either the primary antibody was elimi- 
nated or preabsorbed serum (anti-Pgp-l-free serum or anti- 
band 3-free serum) was used (Fig. 4,  C and D). 
Interaction of  GP85 with Ankyrin 
Colocalization of Lymphoma GP85 Glycoprotein and An- 
kyr/n. In a previous study, lymphoma GP85 has been shown 
to be closely associated with lymphocyte ankyrin-like mole- 
cules (9). In order to verify this finding, we have used double 
immunofluorescent staining to simultaneously localize GP85 
and  intracellular  membrane  linkers,  such  as  ankyrin,  in 
lymphocytes. Our results showed that there was a preferen- 
tial  accumulation  of intracellular ankyrin directly under- 
neath GP85 caps (Fig. 7, A and B) indicating a close associa- 
tion between GP85 and ankyrin. 
Demonstration  of the Specific Binding  between GP85 
and uSI-Ankyrin. Binding between the erythrocyte band 3 
protein and ankyrin has been extensively studied in recon- 
stitution experiments that employ inside out erythrocyte  vesi- 
cles and purified ankyrin (6, 38). However, in the lympho- 
cyte system  it  is  difficult to  obtain  inside  out  membrane 
vesicles. Therefore, GP85 was  reconstituted into synthetic 
phospholipid vesicles (liposomes) in order to examine the 
possibility of direct ankyrin binding to the cytoplasmic do- 
main of GP85. The material used in this experiment is de- 
scribed in Fig. 3, which shows that GP85 was the only sur- 
face protein incorporated in the phospholipid vesicles. GP85, 
metabolically labeled with 32po4, was used to establish the 
orientation of the GP85 incorporated into phospholipid vesi- 
cles (Fig.  8, A and  C).  The fact that •50%  of the a2PO4- 
labeled material (Fig. 8 A) could be released from the lipo- 
some by trypsin digestion (Fig. 8 B1-3) suggests that a large 
portion of the 32PO4-1abeled GP85's cytoplasmic domain is 
protruding from the outside surface of the phospholipid vesi- 
cle. Consequently, these protruding portions of the GP85's 
cytoplasmic  domain  (analogous  to  the  inside  out  vesicle 
preparation in erythrocytes) should be available for an anky- 
rin  binding.  The  GP85-containing  phospholipid  vesicles 
(showing available cytoplasmic domain) were then used to 
carry out  ~25I-ankyrin-binding  assays.  Our results showed 
that there was a fivefold increase in  t25I-ankyrin binding to 
the GP85-containing vesicles (Fig. 8 D), as compared with 
the control liposomes that were either treated with trypsin 
or did not contain any GP85 (Fig. 8 E). These experiments 
all indicate that GP85 binds directly to ankyrin. 
Another approach used in this study involved labeling all 
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32po4-1abeled  glycoprotein- 
containing phospholipid vesi- 
cles  (liposomes)  by  sucrose 
gradient  centrifugation  and 
SDS-PAGE.  Both surface 125I- 
labeled  and  metabolically 
32PO4-1abeled  WGA-binding 
proteins  (prepared  according 
to the procedures described in 
Fig.  1) were incorporated into 
phospholipid  vesicles.  These 
glycoprotein-containing phos- 
pholipid vesicles (liposomes) 
were analysed by sucrose gra- 
dient  centrifugation  as  de- 
scribed  in  the  Materials  and 
Methods.  (Curve  A)  The 
sedimentation profile of lipo- 
somes containing surface 12~I- 
labeled  WGA-specific  glyco- 
proteins.  (Curve  B)  The 
sedimentation profile of lipo- 
somes  containing  metaboli- 
cally 32PO4-1abeled WGA-spe- 
cific glycoproteins.  (Lane C) 
Autoradiogram of surface usI- 
labeled  WGA-specific  gly- 
coprotein obtained from curve 
A.  (Note that the  GP85  was 
selectively  incorporated  into 
liposomes.) 
the  GP85  molecules  with  ~25I and  incubating  these  mole- 
cules with ankyrin-conjugated Sepharose beads. Our results 
showed  that  ~25I-labeled  GP85  specifically  bound  to  the 
ankyrin beads (Fig. 9 A). As a control, the GP85 was prein- 
cubated with an excess amount of unlabeled ankyrin. Under 
Figure  4.  Immunoprecipita- 
tion of lymphoma Pgp-I  and 
band 3-like molecules. (Lanes 
A  and  B)  Immunoprecipita- 
tion autoradiogram of surface 
~2SI-labeled WGA-binding pro- 
teins  (prepared  according  to 
Fig.  1 A)  incubated  with ei- 
ther  rat  anti-Pgp-1  monoclo- 
hal antibody 0ane A) or rabbit 
antierythroc~yte band 3 antise- 
rum (lane B) followed by goat 
anti-rat immunoglobulin (IgG) 
and  goat  anti-rabbit  IgG, 
respectively. (Lane C) Auto- 
radiogram of control samples 
in which the primary antibody 
was omitted. (Lane D) Auto- 
radiogram of control samples 
in which the preabsorbed an- 
tiserum  (anti-Pgp-l-free  se- 
rum  or anti-band  3-free  se- 
rum) was used. 
Figure 5. Two-dimensional gel electrophoresis: isoelectric focusing 
(IEF) and SDS-PAGE analysis of surface 12SI-labeled  GP85. Auto- 
radiogram of surface  12Sl-labeled GP85  analyzed by two-dimen- 
sional gel electrophoresis. First dimension, IEF gel with a pH gra- 
dient from 4.5 (left) to 7. 5 (right). Second dimension, 5-15 % linear 
polyacrylamide gradient gels containing SDS.  (A similar two-di- 
mensional gel pattern was observed when  t25I-labeled Pgp-1 was 
used as a  marker standard,  data not shown). 
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pattern of surface mI-labeled 
GP85.  Peptide  fragments of 
surface-labeled m25I were ob- 
tained by limited proteolysis 
with V-8 protease as described 
in  Materials  and  Methods. 
(Lane A) Intact GP85 without 
protease treatment;  (lane B) 
peptide  fragments  of  GP85 
treated with 1 p.g of V-8 pro- 
tease;  (lane C) peptide frag- 
ments  of GP85  treated  with 
5 I.tg of V-8 protease.  (Simi- 
lar peptide mapping patterns 
were observed when 125I-Pgp- 
1 was  treated with  V-8 pro- 
tease, data not shown.) 
Figure  7.  Double  immuno- 
fluorescence staining of lym- 
phoma cells for localization of 
surface GP85 (Pgp-l) (A) and 
intracellular  ankyrin  (B). 
Bar, 12 Ixm. 
this condition, the binding of GP85 to the ankyrin beads de- 
creased significantly (Fig. 9 B). When GP85 (Fig. 10 A) was 
partially digested by trypsin into several fragments (i.e., 40 
and 22 kD; Fig.  10 B), only the intact GP85 molecule and 
the 40-kD (but not 22-kD proteolytic fragments preferen- 
tially bound to ankyrin beads (Fig.  10 C). When metaboli- 
cally 32PO4-1abeled GP85 was extensively digested by tryp- 
sin, the 40-kD phosphorylated (but not 22-kD) peptide also 
specifically bound to the ankyrin beads (Fig. 10 D). This as- 
say showed that the association between the 40-kD peptide 
and the ankyrin beads was specific (Fig.  11 A) because free 
excess soluble ankyrin successfully competed with the pep- 
tide for ankyrin binding sites on the beads (Fig. 11 B). There- 
fore, it is suggested that the 40-kD proteolytic fragment of 
GP85 contains the ankyrin binding site. 
Discussion 
In this study we have found that lymphoma GP85 is a trans- 
membrane glycoprotein that displays the following charac- 
teristics:  (a) it can be surface-labeled with Nat25I (Fig.  1); 
(b) it contains WGA-binding sites (Fig. 1); (c) its cytoplasmic 
Figure 8. Analysis of 32PO4-1abeled  GP85-associ- 
ated liposomes by a Sepharose 2B-300 column. 
(Curve  A)  32pO4-GP85-associated  liposomes 
without trypsin  treatment.  (Note that  only one 
peak at void volume represents the intact form of 
labeled  GP85-associated liposomes.  (Curve  B) 
32PO4-GP85-associated liposomes  treated  with 
trypsin.  (Note the presence of three peaks. The 
peak at void volume represents the remaining in- 
tact GP85-associated liposomes [BL] [due to an 
incomplete digestion by trypsin].  The other two 
peaks,  resolved  by  the  gel  filtration  2B-300 
column,  represent trypsin-digested GP85  mole- 
cules released from the liposome at a smaller het- 
erogeneous size [B2 and B3].) (C) Negative stain- 
ing of 32po4-1abeled GP85-associated lilaosomes 
obtained from curve A. Bar, 0.1 lain. (Curve D) Psi- 
ankyrin binding to liposomes containing unlabeled 
GP85  without trypsin  pretreatment.  (Curve E) 
~25I-ankyrin binding to liposomes containing unla- 
beled  GP85  pretreated  with  trypsin.  (Similar 
results  were  observed  when  12SI-ankyrin was 
bound to liposomes that did not contain GP85.) 
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GP85  to  ankyrin-Sepharose 
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Figure  11.  Binding of the pep- 
tide  fragments  of  (trypsin- 
treated)  125I-GP85 to  ankyrin- 
Sepharose  beads.  The  entire 
GP85 molecule was first labeled 
with '25I. The radioactively la- 
beled  GP85  was  partially  di- 
gested  by  Sepharose-conjugat- 
ed trypsin (immobilized form), 
and  then  incubated  with  an- 
kyrin-Sepharose beads. Peptide 
fragments  of GP85  bound  to 
the  ankyrin-Sepharose  beads 
before  (A)  and  after  (B)  pre- 
treatment with an excess amount 
of soluble ankyrin. 
domain  can  be phosphorylated by intracellular kinase(s), 
primarily on serine and threonine residues (Fig. 2); and (d) 
it  can  be  incorporated into  phospholipid  vesicles,  imply- 
ing the existence of a hydrophobic domain in the molecule 
(Fig.  3). 
Further studies show that lymphoma GP85 exhibits cross- 
reactivity with antibody raised against T lymphocyte Pgp-1 
(Fig. 4, lanes 1 and 3).  Pgp-1  is a 95-kD glycoprotein ex- 
pressed predominantly on the surface of bone marrow pro- 
thymocytes, on T lymphoma cells and on a few thymus cells 
(32-34, 46). The discrepancy between the molecular masses 
Figure  10.  Analysis of ankyrin-binding domain  of GP85  using 
ankyrin-Sepharose beads and SDS-PAGE/autoradiography.  The en- 
tire GP85 molecule was first labeled with  '251. Intact GP85 and 
peptide fragments of  GP85 (partially digested by immobilized tryp- 
sin) were bound to ankyrin-Sepharose beads as described in Mate- 
rials and Methods. (Lane A) Autoradiogram of '25I-labeled intact 
GP85 bound to ankyrin-Sepharose beads. (Lane B) Autoradiogram 
of total trypsin-digested peptide fragments of '25I-labeled  GP85 be- 
fore binding to ankyrin-Sepharose beads (Note that the intact GP85 
and two fragments of  40 and 22 kD were present.) (Lane C) Autora- 
diogram  of peptide  fragments  of  '25I-labeled GP85  bound  to 
ankyrin-Sepharose beads. (Note that both intact GP85 and a frag- 
ment of 40 kD (but not 22 kD) were preferentially bound to the 
ankyrin-Sepharose  beads.)  (Lane  D)  Autoradiogram of peptide 
fragments of metabolically 32po4-1abeled  GP85 bound to ankyrin- 
Sepharose beads. In this case, trypsin digestion of GP85 is more 
complete. (Note that, again, a fragment of 40 kD [but not 22 kD] 
was preferentially bound to the ankyrin-Sepharose beads.) 
determined for Pgp-1 (95 kD) and GP85 (85 kD) could result 
from the different SDS-PAGE systems used by Trowbridge's 
(33,  46) and our laboratories.  The GP85 containing (Pgp- 
1  §  thymocytes include progenitor ceils that are able to home 
back to the thymus of an irradiated animal and proliferate, 
thereby producing a transient thymus repopulation (33). We 
believe that  GP85  (Pgp-1)  plays  an  important role in  the 
differentiation of T  lymphocytes. 
Recently, several authors have suggested that a family of 
cell surface receptors with a common sequence homology 
(called "integrins') are involved in cell adhesion (45), cell 
migration (41), thrombosis (13), and lymphocyte helper- and 
killer-related activities (26, 42).  Integrins include cell sur- 
face receptors for extracellular matrix proteins (26, 30), the 
major glycoprotein complex on the platelet surface (GPI]b- 
IIIa) (13, 26), and several groups of  proteins on lymphoid and 
myeloid cells (LFA-1, MAC-l,  P150,95  and VLA antigens) 
(26). Lymphocyte  integrin, LFA-1, acts as a general adhesion 
protein that participates in cell-mediated killing and antigen- 
specific helper activity (26,  30).  LFA-1 is composed of an 
a-subunit with a molecular mass of ~180 kD and a I]-subunit 
with a molecular mass of 85-95 kD (30). The fact that lym- 
phoma 85 and 180 kD (gp 180) can be coisolated from WGA 
columns (Fig. 1), and cosedimented on a sucrose gradient as 
a large complex (data not shown), suggests that lymphoma 
GP85 may be a subunit of lymphocyte integrin. In addition, 
transmembrane interactions appear to occur between inte- 
grins and the cytoskeleton (13, 26, 30) during various cellular 
events. However, at present, little is known about the link- 
age between the lymphocyte integrin molecule and the cyto- 
skeleton. 
Currently,  the  most  extensively  characterized  plasma 
membrane-cytoskeleton organization is that of erythrocytes 
(1, 2, 6, 17, 38). The predominant linkage between the eryth- 
rocyte cytoskeleton and membrane occurs at the anion chan- 
nel, band 3 (40). Band 3 protein binds via its cytoplasmic do- 
main to the linker molecule, ankyrin. Ankyrin binds to the 
band 3 molecule through high affinity sites (24) and possibly 
through a  lipid molecule, palmitate (39, 43).  Ankyrin also 
binds to the actin-binding protein, spectrin (10, 23), complet- 
ing the linkage between the membrane and the cytoskeleton. 
The cytoplasmic domain of erythrocyte  band 3 is a known 
substrate for endogenous and exogenous protein kinases, in- 
cluding tyrosine kinase (40).  Several investigators using a 
limited proteolysis of erythrocyte band 3 have demonstrated 
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domain) contains the ankyrin-binding site (4, 40). Recently, 
Davis and Bennett reported that a  proteolytic  fragment of 
brain membrane-associated ankyrin-binding protein is simi- 
lar in size (molecular mass, 40 kD) to the cytoplasmic do- 
main of the erythrocyte band 3 (18).  These data suggest that 
the membrane-associated  ankyrin-binding  domain may be 
present  in  different  cell  types  (18).  Another  erythrocyte 
membrane-associated  skeletal  protein,  band 4.1,  has been 
shown to associate with band 3 via low affinity binding sites 
(40). It is not known whether lipids play any role in the link- 
age of band 3 and the 4.1 protein or whether band 3-4.1 pro- 
tein complex is present in nonerythroid cells.  At the time, 
many unanswered questions remain concerning the proper- 
ties of these linkages, particularly with regard  to the mem- 
brane-associated binding domain(s) for the cytoskeleton. 
In this paper,  we have presented evidence that GP85 of 
mouse T lymphoma cells is very similar, if not equivalent, 
to erythrocyte band 3 glycoprotein. Our results indicate that 
lymphoma GP85 has erythrocyte band 3-like properties be- 
cause it is a transmembrane glycoprotein  and cross-reacts 
with specific  antibodies  raised against erythrocyte  band 3 
molecules. In erythrocytes, inside out (reversed) vesicles are 
used  extensively  to  elucidate  transmembrane-cytoskeletal 
interactions.  However, in nonerythrocytes,  it is difficult to 
prepare  inside  out vesicles.  Therefore,  it  is  necessary  to 
reconstitute the membrane glycoprotein  in synthetic phos- 
pholipid vesicles  (Fig.  3) and perform binding studies be- 
tween  GP85  and  ankyrin  (Fig.  8).  Our preliminary  data 
using silver-stained SDS-PAGE and autoradiographic analy- 
ses indicate that GP85 is the major silver-stained (data not 
shown), surface-iodinated, and phosphorylated protein (Figs. 
1-3).  Using  this method with  studies employing  ankyrin- 
conjugated sepharose beads, we have also found that GP85 
binds directly to ankyrin (Fig. 9) and that the cytoplasmic do- 
main of GP85, a 40-kD proteolytic fragment (Figs.  10 and 
11) contains the ankyrin binding site.  This transmembrane 
linkage through GP85 and ankyrin to the cytoskeleton could 
play a pivotal role in a number of important physiological ac- 
tivities,  such as receptor capping,  cell activation,  cell-cell 
interaction, and cell adhesion. More work is needed to deter- 
mine the precise  sequences  involved in GP85  for ankyrin 
binding, and to investigate whether GP85 is an anionic trans- 
porter for lymphocytes and also an integrin subunit. 
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